a developer and marketer of prescription pharmaceutical products for the treatment of gastrointestinal diseases, is recently down $2.51 to $9.01. Weakness was attributable to concerns of Colazal generic competition. SLXP call option volume of 9,940 contracts compares to put volume (register to read more …)